NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
äŒæ¥ã³ãŒãNEO
äŒç€ŸåNeogenomics Inc
äžå Žæ¥Dec 10, 2012
æé«çµå¶è²¬ä»»è
ãCEOãZook (Antony P)
åŸæ¥å¡æ°2200
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Dec 10
æ¬ç€Ÿæåšå°9490 Neogenomics Way
éœåžFORT MYERS
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·33912
é»è©±çªå·12397680600
ãŠã§ããµã€ãhttps://neogenomics.com/
äŒæ¥ã³ãŒãNEO
äžå Žæ¥Dec 10, 2012
æé«çµå¶è²¬ä»»è
ãCEOãZook (Antony P)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã